<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267149</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-2010</org_study_id>
    <nct_id>NCT01267149</nct_id>
  </id_info>
  <brief_title>A Clinical Study Evaluaing the Efficacy, Safety, and Patient Satisfaction of Injectable Hylaronic Acid With 0.3% Lidocain Hydrochloride, Prevelle Silk, for Superficial, Vertical Perioral Lines and Superficial, Horizontal, Lateral Canthal Lines</brief_title>
  <official_title>Phase 4 Study - A Clinical Study Evaluaing the Efficacy, Safety, and Patient Satisfaction of Injectable Hylaronic Acid With 0.3% Lidocain Hydrochloride, Prevelle Silk, for Superficial, Vertical Perioral Lines and Superficial, Horizontal, Lateral Canthal Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldman, Butterwick, Fitzpatrick and Groff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mentor Worldwide, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Goldman, Butterwick, Fitzpatrick and Groff</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statistical Hypotheses The Null Hypothesis: There is no difference in the reduction of lines
      in the treated areas as compared to baseline.

      Alternative Hypothesis: There is a difference in the reduction of lines in the treated areas
      as compared to baseline.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Wrinkles</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Cosmetic Dermatology Practice Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females and males in good general health between 35 to 65 years of age.

          -  Must be willing to give and sign a HIPPA form, informed consent form and a
             photographic release form

          -  Patient is planning to undergo Prevelle Silk treatment

          -  A potential subject's must exhibit:

        A. moderate to severe superficial, vertical perioral and horizontal canthus lines

          -  For FEMALE PATIENT OF CHILDBEARING POTENTIAL, must have had a regular menstrual cycle
             prior to study entry (a female is considered of childbearing potential unless she is
             postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal
             ligation) and is willing to use an acceptable form of birth control during the entire
             course of the study [i.e., acceptable methods of birth control are oral
             contraceptives, contraceptive patches/rings/implants Norplanit®, Depo-Provena®,
             double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of
             partner with a documented second acceptable method of birth control should the patient
             become sexually active]. All systemic birth control measures must be in consistent use
             at least 30 days prior to study participation

          -  Negative urine pregnancy test results at the time of study entry (if applicable)

          -  Must be willing to comply with study regimen and complete the entire course of the
             study.

        Exclusion Criteria:

          -  A patient with any UNCONTROLLED systemic disease. A potential patient in whom therapy
             for a systemic disease is not yet stabilized will not be considered for entry into the
             study

          -  A patient with a significant history or current evidence of a medical, psychological
             or other disorder that, in the investigator's opinion, would preclude enrollment into
             the study.

          -  A patient with a known hypersensitivity to any of the components of the study
             medications

          -  A patient who is actively smoking or plans to smoke at any time of the duration of
             this study

          -  A patient with an active skin condition/disease that might interfere with the
             diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema,
             psoriasis, seborrheic dermatitis, herpes labialis)

          -  A patient planning any other cosmetic procedure to their facial area during the study
             period, other than the treatments that will be performed by the investigator

          -  A patient using any topical (prescription or over the counter) medicated creams,
             lotions, gels, balms, powders, etc. on the treatment areas during the study period

          -  A patient receiving any topical products containing alpha-hydroxy acids, salicylic
             acid, and vitamins C or D (includes derivatives thereof) on the perioral or lateral
             canthal areas within 7 days prior to or during the study period, other than the study
             products

          -  A patient receiving any investigational drug and/or has had a microdermabrasion (light
             or medium skin peel) treatment on their perioral or lateral canthal areas within 30
             days prior to or during the study period

          -  A patient using any topical tretinoin product or derivative on their perioral or
             lateral canthal areas within 12 weeks prior to or during the study period

          -  A patient receiving a chemical peel, any systemic steroids, a non-ablative laser,
             light or radio frequency treatment and/or has had a Dermabrasion (deep skin peel) or
             ablative laser treatments on their perioral or lateral canthal areas must have
             discontinued the drug/treatment and/or had the procedure at least 6 months prior to
             entering the study

          -  A patient that has previously been treated with botulinum toxin in the perioral or
             lateral canthal areas within the past six months

          -  A patient that has previously been treated with dermal filler in the perioral or
             lateral canthal areas within the past year

          -  A patient that with a history of allergic reaction to a dermal filler or lidocaine

          -  A patient that with a history of a permanent filler to the perioral or lateral canthal
             areas

          -  A female patient who is pregnant, nursing an infant or planning a pregnancy during the
             study [throughout the course of the study, women of child-bearing potential must use
             reliable forms of contraception (i.e., oral contraceptive, intrauterine device,
             abstinence, or spermicides and condoms used in combination)]

          -  Current participation or participation within 30 days prior to the start of this study
             in a drug or other investigational research study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell P Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology and Cosmetic Laser Associated La Jolla</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karina Brazdys, RN</last_name>
    <phone>858-657-1002</phone>
    <phone_ext>109</phone_ext>
    <email>kbrazdys@gbk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna Perez</last_name>
    <phone>858-657-1002</phone>
    <phone_ext>120</phone_ext>
    <email>dperez@gbkderm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Goldman, Butterwick, Fitzpatrick and Groff</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Brazdys, RN</last_name>
      <phone>858-657-1002</phone>
      <phone_ext>109</phone_ext>
      <email>kbrazdys@gbkderm.com</email>
    </contact>
    <contact_backup>
      <last_name>Donna Perez</last_name>
      <phone>858-657-1002</phone>
      <phone_ext>120</phone_ext>
      <email>dperez@gbkderm.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell P. Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Maas Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Shamban</last_name>
      <phone>415-567-7000</phone>
      <email>research@maasclinic.com</email>
    </contact>
    <investigator>
      <last_name>Corey Mass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2010</study_first_posted>
  <last_update_submitted>December 27, 2010</last_update_submitted>
  <last_update_submitted_qc>December 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mitchell Goldman MD</name_title>
    <organization>Goldman, Butterwick, Fitzpatrick and Groff</organization>
  </responsible_party>
  <keyword>superficial vertical perioral lines</keyword>
  <keyword>superficial horizontal and lateral canthal lines</keyword>
  <keyword>correct moderate to severe facial wrinkles and folds</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

